DongKoo Bio & Pharma Co. Ltd. (006620) - Total Assets
Based on the latest financial reports, DongKoo Bio & Pharma Co. Ltd. (006620) holds total assets worth ₩318.60 Billion KRW (≈ $215.91 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
DongKoo Bio & Pharma Co. Ltd. - Total Assets Trend (2015–2025)
This chart illustrates how DongKoo Bio & Pharma Co. Ltd.'s total assets have evolved over time, based on quarterly financial data. Also see 006620 company net worth for the company's overall valuation and market capitalisation.
DongKoo Bio & Pharma Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2025)
DongKoo Bio & Pharma Co. Ltd.'s total assets of ₩318.60 Billion consist of 37.6% current assets and 62.5% non-current assets. Review DongKoo Bio & Pharma Co. Ltd. balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 6.4% |
| Accounts Receivable | ₩19.34 Billion | 5.8% |
| Inventory | ₩50.00 Billion | 14.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩8.32 Billion | 2.5% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how DongKoo Bio & Pharma Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of DongKoo Bio & Pharma Co. Ltd. for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DongKoo Bio & Pharma Co. Ltd.'s current assets represent 37.6% of total assets in 2025, a decrease from 40.9% in 2015.
- Cash Position: Cash and equivalents constituted 6.4% of total assets in 2025, up from 0.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, unchanged from 2.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 14.9% of total assets.
DongKoo Bio & Pharma Co. Ltd. Competitors by Total Assets
Key competitors of DongKoo Bio & Pharma Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Theragen Etex Co.Ltd
KQ:066700
|
Korea | ₩253.33 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩575.39 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩222.34 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩98.92 Billion |
|
Komipharm International Co. Ltd
KQ:041960
|
Korea | ₩133.92 Billion |
|
Caregen Co.Ltd
KQ:214370
|
Korea | ₩233.98 Billion |
DongKoo Bio & Pharma Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.90 | 0.92 | 1.56 |
| Quick Ratio | 0.62 | 0.39 | 1.11 |
| Cash Ratio | 0.00 | 0.00 | 0.47 |
| Working Capital | ₩-13.40 Billion | ₩-8.42 Billion | ₩26.24 Billion |
DongKoo Bio & Pharma Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between DongKoo Bio & Pharma Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.67 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 37.8% |
| Total Assets | ₩336.35 Billion |
| Market Capitalization | $22.84 Million USD |
Valuation Analysis
Below Book Valuation: The market values DongKoo Bio & Pharma Co. Ltd.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: DongKoo Bio & Pharma Co. Ltd.'s assets grew by 37.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for DongKoo Bio & Pharma Co. Ltd. (2015–2025)
The table below shows the annual total assets of DongKoo Bio & Pharma Co. Ltd. from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩336.35 Billion ≈ $227.94 Million |
+37.81% |
| 2024-12-31 | ₩244.06 Billion ≈ $165.40 Million |
+27.71% |
| 2023-12-31 | ₩191.10 Billion ≈ $129.51 Million |
+11.07% |
| 2022-12-31 | ₩172.06 Billion ≈ $116.60 Million |
+11.16% |
| 2021-12-31 | ₩154.79 Billion ≈ $104.90 Million |
+7.23% |
| 2020-12-31 | ₩144.35 Billion ≈ $97.83 Million |
+8.76% |
| 2019-12-31 | ₩132.73 Billion ≈ $89.95 Million |
+27.28% |
| 2018-12-31 | ₩104.28 Billion ≈ $70.67 Million |
+37.95% |
| 2017-12-31 | ₩75.59 Billion ≈ $51.23 Million |
+15.74% |
| 2016-12-31 | ₩65.31 Billion ≈ $44.26 Million |
+7.47% |
| 2015-12-31 | ₩60.77 Billion ≈ $41.18 Million |
-- |
About DongKoo Bio & Pharma Co. Ltd.
DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral,… Read more